Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Toxicology
Erschienen in: Cardiovascular Toxicology 2/2017

22.03.2016

Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy

verfasst von: Ghasem Janbabai, Maryam Nabati, Mohsen Faghihinia, Soheil Azizi, Samaneh Borhani, Jamshid Yazdani

Erschienen in: Cardiovascular Toxicology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Anthracycline (ANT) is a topoisomerase-interacting agent that is used in most malignancy treatments. We investigated the efficacy of enalapril (angiotensin-converting enzyme inhibitor) in the prevention of ANT-induced cardiomyopathy. In this randomized, single-blind, and placebo-controlled study, 69 patients with a newly diagnosed malignancy for which ANT therapy was planned were randomly assigned to either a group receiving enalapril (n = 34) or placebo (n = 35). Echocardiography studies were performed before chemotherapy and at 6 months after randomization. Additionally, troponin I and creatinine kinase-MB (CK-MB) were measured 1 month after the initiation of chemotherapy. In the enalapril group, the mean left ventricular ejection fraction (LVEF) (p = 0.58) was the same at baseline and 6 months after randomization. Conversely, LVEF significantly decreased in the control group (p < 0.001). Additionally, LV end systolic volume and left atrial diameter were significantly increased compared with the baseline measures in the control group. According to the tissue Doppler study, the mitral annuli early diastolic (e′) and peak systolic (s′) velocities were significantly reduced, and the E (the peak early diastolic velocity)/e′ ratio was significantly increased in the control group. Furthermore, the TnI and CK-MB levels were significantly higher in the control group than in the enalapril group. Enalapril appears efficacious in preserving systolic and diastolic function in cancer patients treated with ANTs.
Literatur
1.
DeVita, V. T., Lawrence, T. S., Rosenberg, S. A., DePinho, R. A., & Weinberg, R. A. (Eds.). (2011). DeVita, Hellman, and Rosenberg’s Cancer: Principles and practice of oncology (9th ed., pp. 404–407). Philadelphia, PA: Lippincott Williams & Wilkins.
2.
Vejpongsa, P., & Yeh, E. T. (2014). Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities. Journal of the American College of Cardiology, 64(9), 938–945.CrossRefPubMed
3.
Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., et al. (2010). Anthracycline-induced cardiomyopathy clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology, 55(3), 213–220.CrossRefPubMed
4.
Sawyer, D. B., Peng, X., Chen, B., Pentassuglia, L., & Lim, C. C. (2010). Mechanisms of anthracycline cardiac injury: Can we identify strategies for cardioprotection? Progress in Cardiovascular Diseases, 53(2), 105–113.CrossRefPubMedPubMedCentral
5.
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., et al. (2009). 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 53, 1343–1382.CrossRef
6.
Sacco, G., Bigioni, M., & Evangelista, S. (2001). Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. European Journal of Pharmacology, 414, 71–78.CrossRefPubMed
7.
Vaynblat, M., Shah, H. R., Bhaskaran, D., Ramdev, G., Davis, W. J, 3rd, Cunningham, J. N, Jr, & Chiavarelli, M. (2002). Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. European Journal of Heart Failure, 4, 583–586.CrossRefPubMed
8.
Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., et al. (2006). Prevention of high-risk chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation, 114, 2474–2481.CrossRefPubMed
9.
Bosch, X., Rovira, M., Sitges, M., Domènech, A., Ortiz-Pérez, J. T., de Caralt, T. M., et al. (2013). Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathiesthe OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). Journal of the American College of Cardiology, 61(23), 2355–2362.CrossRefPubMed
10.
Pfeffer, B., Tziros, C., & Katz, R. J. (2009). Current concepts of anthracycline cardiotoxicity: Pathogenesis, diagnosis and prevention. British Journal of Cardiology, 16(2), 85–89.
11.
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L, Jr, et al. (2003). Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, 1206–1252.CrossRefPubMed
12.
American Diabetes Association. (2010). Diagnosis and classification of diabetes mellitus. Diabetes Care, 33(Suppl 1), S62–S69.CrossRefPubMedCentral
13.
Arnett, D. K., Jacobs, D. R., Luepker, R. V., Blackburn, H., Armstrong, C., & Claas, S. A. (2005). Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use The Minnesota Heart Survey, 1980–1982 to 2000–2002. Circulation, 112(25), 3884–3891.CrossRefPubMed
14.
Silber, J. H., Cnaan, A., Clark, B. J., Paridon, S. M., Chin, A. J., Rychik, J., et al. (2004). Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology, 22, 820–828.CrossRefPubMed
15.
Barrett-Lee, P., Dixon, J., Farrell, C., Jones, A., Leonard, R., Murray, N., et al. (2009). Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Annals of Oncology, mdn728.
16.
Perez, E. A., Suman, V. J., Davidson, N. E., Kaufman, P. A., Martino, S., Dakhil, S. R., et al. (2004). Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. Journal of Clinical Oncology, 22, 3700–3704.CrossRefPubMed
17.
Nagueh, S. F., Appleton, C. P., Gillebert, T. C., Marino, P. N., Oh, J. K., Smiseth, O. A., et al. (2009). Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Journal of the American Society of Echocardiography, 22(2), 107–133.CrossRefPubMed
18.
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., et al. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography, 27(9), 911–939.CrossRefPubMed
Metadaten
Titel
Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy
verfasst von
Ghasem Janbabai
Maryam Nabati
Mohsen Faghihinia
Soheil Azizi
Samaneh Borhani
Jamshid Yazdani
Publikationsdatum
22.03.2016
Verlag
Springer US
Erschienen in
Cardiovascular Toxicology / Ausgabe 2/2017
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI
https://doi.org/10.1007/s12012-016-9365-z

Weitere Artikel der Ausgabe 2/2017

Cardiovascular Toxicology 2/2017 Zur Ausgabe

OriginalPaper

The Correlation Between 9p21 Chromosome rs4977574 Polymorphism Genotypes and the Development of Coronary Artery Heart Disease

OriginalPaper

Acrolein Inhalation Alters Myocardial Synchrony and Performance at and Below Exposure Concentrations that Cause Ventilatory Responses

OriginalPaper

Anti-apoptotic and Pro-survival Effects of Food Restriction on High-Fat Diet-Induced Obese Hearts

OriginalPaper

Role of Oxygen Free Radicals, Nitric Oxide and Mitochondria in Mediating Cardiac Alterations During Liver Cirrhosis Induced by Thioacetamide

OriginalPaper

Low-level Chronic Lead Exposure Impairs Neural Control of Blood Pressure and Heart Rate in Rats

OriginalPaper

Anti-atrial Fibrillatory Versus Proarrhythmic Potentials of Amiodarone: A New Protocol for Safety Evaluation In Vivo